Nasal Corticosteroids for Allergic Rhinitis and Chronic Rhinosinusitis
For adults with allergic rhinitis or chronic rhinosinusitis, intranasal corticosteroids are the most effective monotherapy and should be first-line treatment, with mometasone furoate 200 μg once daily or fluticasone propionate 200 μg once daily being optimal choices based on efficacy, safety profile, and minimal systemic bioavailability. 1, 2, 1
Allergic Rhinitis: Specific Agent and Dosing
Intranasal corticosteroids (INCS) represent the most effective single medication class for controlling all four major symptoms of allergic rhinitis: sneezing, itching, rhinorrhea, and particularly nasal congestion 1. The evidence consistently demonstrates superiority over oral antihistamines, leukotriene receptor antagonists, and intranasal antihistamines 1, 3.
Recommended First-Line Agents:
Mometasone furoate (Nasonex):
- Adults: 2 sprays (100 μg) per nostril once daily (total 200 μg/day) 2
- Can reduce to 1 spray per nostril once daily for maintenance after symptom control
- Demonstrated significant symptom improvement versus placebo and amoxicillin in multiple trials 4
- Minimal systemic bioavailability with excellent safety profile 5
Fluticasone propionate (Flonase):
- Adults: 2 sprays (100 μg) per nostril once daily (total 200 μg/day) 2
- Alternative: 1 spray per nostril once daily for milder symptoms
- Rapid onset of action (within 12-24 hours) 1, 6
- Available over-the-counter, improving accessibility
Fluticasone furoate (Veramyst):
- Adults: 2 sprays (55 μg) per nostril once daily (total 110 μg/day) 2
- Newer formulation with optimized pharmacokinetics 7
- Demonstrated 24-hour efficacy with once-daily dosing
Alternative Agents:
- Triamcinolone acetonide: 220 μg once daily (maximum dose) 2, 8
- Budesonide: 200 μg once daily 2
- Ciclesonide (Omnaris): 2 sprays per nostril once daily (200 μg total) 2
- Beclomethasone dipropionate: 320 μg/day for optimal efficacy 9
Chronic Rhinosinusitis: Specific Recommendations
For chronic rhinosinusitis (CRS), INCS remain first-line therapy with evidence supporting their use in both CRS with nasal polyps (CRSwNP) and without polyps (CRSsNP) 10, 11.
Standard Dosing for CRS:
Mometasone furoate:
- CRSwNP: 2 sprays (100 μg) per nostril twice daily (total 400 μg/day) 4
- Can use 200 μg twice daily as alternative dosing
- Duration: 15-21 days for acute exacerbations, ongoing for chronic management
Fluticasone propionate:
- 2 sprays per nostril twice daily 4
- Particularly effective post-viral acute rhinosinusitis
Post-Surgical Management:
For patients with moderate-to-severe CRS not controlled with standard INCS after endoscopic sinus surgery:
- Budesonide nasal irrigations (off-label use, not FDA-approved) 10
- Consider exhalation delivery systems (EDS) with fluticasone for enhanced delivery 10, 11
- Steroid-eluting stents for select cases with recurrent polyposis 10
Critical Administration Technique
Proper technique is essential to maximize efficacy and minimize adverse effects 10:
- Shake bottle well before use
- Look down (bend neck, look toward floor)
- Use contralateral hand (right hand for left nostril, left hand for right nostril)
- Aim toward outer wall of nose - NOT toward the nasal septum
- Do not sniff hard after administration
- Spray once or twice per nostril as directed
This technique prevents septal irritation, epistaxis, and potential septal perforation 1.
Dosing Strategies
Continuous daily dosing is most effective for seasonal and perennial allergic rhinitis 1. However, for seasonal allergic rhinitis specifically:
- PRN dosing (>50% of days) can be effective but may result in breakthrough symptoms 1, 12
- Start therapy before symptom onset when possible for seasonal allergies 1
- Onset of action typically occurs within 3-12 hours, with maximum benefit at 12-24 hours 1
For severe symptoms:
- May use twice-daily dosing initially, then reduce to once-daily for maintenance 2
- Consider short course (5-7 days) of oral corticosteroids for very severe intractable symptoms, then maintain with INCS 1
Safety Profile and Monitoring
Modern INCS formulations (mometasone, fluticasone propionate, fluticasone furoate, ciclesonide) demonstrate minimal systemic absorption due to extensive first-pass metabolism and low oral bioavailability 5.
At recommended doses, INCS do NOT cause:
- Clinically significant HPA axis suppression 1, 5
- Growth suppression in children (except beclomethasone at supra-therapeutic doses) 1
- Increased intraocular pressure or cataract formation 1, 5
- Bone density changes 1
Common local adverse effects (generally mild):
Monitoring recommendations:
- Examine nasal septum periodically for mucosal erosions (may precede perforation) 1
- Septal perforation is rare but requires proper technique to prevent 1
- No routine laboratory monitoring required for systemic effects at therapeutic doses 10
Common Pitfalls to Avoid
- Incorrect spray direction: Aiming toward septum causes irritation and bleeding - always aim laterally 10
- Premature discontinuation: Patients may stop therapy before achieving maximum benefit (typically 1-2 weeks) 1
- Using parenteral corticosteroids: Single or recurrent IM corticosteroid injections are contraindicated due to prolonged adrenal suppression and local complications 1
- Inadequate trial duration: Minimum 2-week trial needed to assess efficacy 1
- Not considering combination therapy: If INCS alone insufficient, add intranasal antihistamine rather than switching 3, 13
When INCS Alone Are Insufficient
If symptoms persist despite optimal INCS therapy:
- Add intranasal antihistamine (azelastine) for rapid symptom relief 1, 2, 3
- Consider fixed-combination INAH+INCS products 13
- For CRSwNP refractory to medical therapy: biologics (dupilumab, mepolizumab, omalizumab) 11
- Surgical intervention for anatomic obstruction or refractory CRS 10
The choice between specific INCS agents should prioritize formulations with lowest systemic bioavailability (mometasone furoate, fluticasone propionate, fluticasone furoate, ciclesonide) over older agents (beclomethasone, triamcinolone) when long-term therapy is anticipated 5, 13.